M. Dinic

Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome.

F. Berthoux, N. Maillard, C. Mariat, 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Resistant Hypertension and Atherosclerotic Renal Artery Stenosis: Effects of Angioplasty on Ambulatory Blood Pressure. A Retrospective Uncontrolled Single-Center Study.

É. Mousseaux, G. Bobrie, L. Amar, 2019, Hypertension.

Genome‐Wide Association Study of Acute Renal Graft Rejection

M. Georges, D. Abramowicz, M. Abramowicz, 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

UMOD polymorphism rs12917707 is not associated with severe or stable IgA nephropathy in a large Caucasian cohort

D. Abramowicz, L. Thibaudin, M. Abramowicz, 2014, BMC Nephrology.

Deletion Variants of CFHR1 and CFHR3 Associate with Mesangial Immune Deposits but Not with Progression of IgA Nephropathy.

F. Berthoux, N. Maillard, C. Mariat, 2017, Journal of the American Society of Nephrology : JASN.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

Serum cystatin C is a determinant of central pressure augmentation index measured by oscillometric method in renal transplant recipients

N. Maillard, C. Mariat, M. Jannot, 2014, BMC Nephrology.

Validation of the international IgA nephropathy prediction tool in a French cohort beyond 10 years after diagnosis.

N. Maillard, C. Mariat, D. Thibaudin, 2023, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.